800 Leaders Unite to Advance Rapid Diagnostics
Opening New Frontiers in Precision Medicine
WASHINGTON–(BUSINESS WIRE)–#Biomarkers–Responding to the growth of the global point-of-care (POC) diagnostics market, which is projected to exceed $38 billion by 2022 (MarketsandMarkets™), Cambridge Healthtech Institute will expand opportunities to explore POC innovations during its eleventh annual Next Generation Dx Summit, taking place August 20-22, 2019 in Washington, DC.
The global summit will unite more than 800 executives, technology professionals, pathologists, and academic and clinical researchers who are forging new frontiers in rapid diagnostics—the “bridge” supporting the successful and safe delivery of precision medicine—with the potential to uncover cancer and infectious diseases at their earliest stages, eliminate unnecessary biopsies, predict responses to innovative therapies and more.
“Point-of-care testing, in particular, stands to revolutionize many aspects of medicine, and the range of tests being imagined is growing along with a consumer base who are hungry for them,” said Christina Lingham, Executive Director, Conferences and Fellow at Cambridge Healthtech Institute.
A POCT and Infectious Disease stream will include three tracks on Enabling Point-of-Care Diagnostics, Emerging Technologies at the Point-of-Care, and Molecular Diagnostics for Infectious Disease. Dozens of presentations will cover microfluidics, the epigenome, lateral flow immunoassays, wearable and imaging data, apps, multiplexing, AI, NGS and clinical metagenomics sequencing, and reimbursement, among other topics. Each track will also feature in-depth short courses and breakfast breakout sessions.
Moreover, the event will feature three new POC Special Forums on Veterinary Applications, Product Strategies, and POC in the Pharmacy.
With experts from the FDA, Guardant Health, Johns Hopkins University, Merck & Co., Memorial Sloan Kettering Cancer Center, and other leaders sharing insights, case studies and data, highlights of the Next Generation Dx Summit include:
- Content streams on Digital Pathology and AI, Liquid Biopsy, Immuno-Oncology, Companion Diagnostics, and Business (coverage, reimbursement, and commercialization)
- Plenary Keynote Sessions on FDA Updates and Proposals/Solutions for Diagnostic Reform
- An Exhibit Hall with 60+ cutting-edge exhibitors, poster sessions, and opportunities for One-on-One Meetings with top prospects
For more information, please see nextgenerationdx.com.
About Cambridge Healthtech Institute
Cambridge Healthtech Institute (CHI), a division of Cambridge Innovation Institute, is the preeminent life science network for leading researchers and business experts from top pharmaceutical, biotech, CROs, academia, and niche service providers. CHI is renowned for its vast conference portfolio held worldwide including PepTalk, Molecular Medicine Tri-Conference, SCOPE Summit, Bio-IT World Conference & Expo, PEGS Summit, Drug Discovery Chemistry, Biomarker World Congress, World Preclinical Congress, The Bioprocessing Summit, Next Generation Dx Summit, Immuno-Oncology Summit, and Discovery on Target. CHI’s portfolio of products include Cambridge Healthtech Institute Conferences, Barnett International, Insight Pharma Reports, Bio-IT World, Clinical Research News and Diagnostics World.
781-449-8456 or email@example.com